The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
pancreatic cancer
Now published in EJC – European Journal of Cancer (1), results of a retrospective study led by investigators of VHIO’s…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with…
